Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Thinkers Wanted: Join the Grassroots Rheumatology Think Tank

David S. Pisetsky, MD, PhD  |  Issue: March 2010  |  March 1, 2010

David S. Pisetsky, MD, PhD

The Congressional struggle over healthcare has been like a heavyweight championship that has gone the distance, with both fighters still standing but bloodied. As of this writing, it is not clear which side has prevailed or even whether both have been knocked silly. Whatever the outcome, however, the battle will not end because the state capitals will join Washington, D.C. as a place where legislation will determine the shape of the healthcare system in the future.

Wherever there is legislation, there are lobbyists, and where there are lobbyists, there is money. Lobbying about healthcare is big business. The spigots of money turned on during the past year will continue to gush as a network of pipelines channel money into capitals from Dover to Des Moines. In view of the myriad issues to resolve by votes, the floodwaters of lobbying money are far from cresting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I have no problems with lobbyists. Indeed, I think that lobbying is an essential part of democracy. The United States is a diverse, rambunctious, and contentious society and disagreements abound. Fortunately, litigation or legislation can usually settle these disagreements. Within this framework, in Washington, the real representatives of the people are often advocacy organizations (a.k.a. lobbyists) that keep their fingers on the legislative pulse, help prepare position statements, arrange meetings with members of Congress, and otherwise promote the agenda of constituents.

Advocacy is only one part of this process. Financial contributions to political campaigns are another. Elections in the United States are unbelievably expensive, with direct financial contributions from political action committees bolstering advocacy efforts. For physicians and other healthcare providers, politics is a murky place and many of us feel uncomfortable there. Nevertheless, efforts like RheumPAC are critical to advancing rheumatology in this country. 2010 is here now and 2012 is not far away.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Ptolemy and Strabo in The School of Athens by Raphael.
Ptolemy and Strabo in The School of Athens by Raphael.

The Cost of Political Speech

While I am great supporter of democracy, with its attendant competition for ideas and dollars, I worry about the future because it turns out that free political speech is not free. In fact, free speech is very, very expensive. The great likelihood is that the price is going to increase. If each state witnesses a legislative struggle of the kind that occurred in Washington, D.C., in 2009, the amount of money expended will total in the tens or even hundreds of millions of dollars. In California, for example, $80 million was recently spent in industry lobbying on an initiative on drug pricing.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & AdvocacyOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:AdvocacyHealthcareLegislationPolitics

Related Articles

    PAC a Punch on Capitol Hill

    May 1, 2007

    New political action committee will be a voice for rheumatology

    Ethics Forum: Personal Ethics Questions Surrounding RheumPAC Donations

    October 14, 2015

    Imagine you’ve just heard a compelling presentation urging all ACR members to contribute to RheumPAC, the ACR’s political action committee. RheumPAC’s mission is to support politicians who support issues important to rheumatologists. You are impressed by the role RheumPAC has played in a number of issues you support. Just as you’re writing a check, you…

    Rheumatology Advocacy Starts at Home

    August 1, 2014

    The ACR expands advocacy efforts to impact state legislatures, local organizations

    A Fork in the Road: Advocacy for Rheumatology

    July 10, 2012

    Is that fork bent? So you must be a rheumatologist.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences